$1.10 Million in Sales Expected for Xeris Pharmaceuticals Inc (NASDAQ:XERS) This Quarter

Equities research analysts forecast that Xeris Pharmaceuticals Inc (NASDAQ:XERS) will report $1.10 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Xeris Pharmaceuticals’ earnings. The highest sales estimate is $1.30 million and the lowest is $890,000.00. Xeris Pharmaceuticals posted sales of $800,000.00 during the same quarter last year, which suggests a positive year-over-year growth rate of 37.5%. The firm is scheduled to announce its next earnings report on Wednesday, March 4th.

On average, analysts expect that Xeris Pharmaceuticals will report full year sales of $1.83 million for the current fiscal year, with estimates ranging from $1.46 million to $2.20 million. For the next financial year, analysts forecast that the company will report sales of $22.69 million, with estimates ranging from $22.17 million to $23.20 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Xeris Pharmaceuticals.

Xeris Pharmaceuticals (NASDAQ:XERS) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($1.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.23) by $0.01. Xeris Pharmaceuticals had a negative return on equity of 150.08% and a negative net margin of 6,697.33%. The business had revenue of $0.32 million during the quarter, compared to analyst estimates of $0.20 million.

A number of equities analysts recently issued reports on XERS shares. Royal Bank of Canada set a $18.00 price objective on Xeris Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 7th. Zacks Investment Research raised Xeris Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 16th. ValuEngine lowered Xeris Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, September 30th. Finally, Mizuho reissued a “buy” rating and issued a $22.00 price objective on shares of Xeris Pharmaceuticals in a report on Thursday, November 21st.

XERS stock traded up $0.14 on Friday, reaching $8.94. The company’s stock had a trading volume of 125,806 shares, compared to its average volume of 196,196. Xeris Pharmaceuticals has a 52 week low of $6.85 and a 52 week high of $20.90. The company has a market capitalization of $241.07 million, a P/E ratio of -1.79 and a beta of -0.39. The firm has a fifty day moving average of $8.34 and a two-hundred day moving average of $10.21. The company has a debt-to-equity ratio of 1.33, a current ratio of 5.96 and a quick ratio of 5.96.

In other news, insider Paul R. Edick purchased 17,935 shares of the firm’s stock in a transaction on Monday, November 25th. The stock was purchased at an average cost of $8.55 per share, with a total value of $153,344.25. Following the purchase, the insider now owns 172,935 shares in the company, valued at approximately $1,478,594.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Steven Prestrelski sold 27,700 shares of the stock in a transaction on Friday, October 11th. The shares were sold at an average price of $9.00, for a total value of $249,300.00. Corporate insiders own 7.43% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Metropolitan Life Insurance Co NY bought a new position in Xeris Pharmaceuticals during the 3rd quarter valued at $100,000. Millennium Management LLC bought a new stake in shares of Xeris Pharmaceuticals during the 3rd quarter worth $918,000. IHT Wealth Management LLC boosted its stake in shares of Xeris Pharmaceuticals by 39.4% during the 3rd quarter. IHT Wealth Management LLC now owns 57,028 shares of the company’s stock worth $561,000 after acquiring an additional 16,114 shares in the last quarter. State Street Corp boosted its stake in shares of Xeris Pharmaceuticals by 17.0% during the 3rd quarter. State Street Corp now owns 466,451 shares of the company’s stock worth $4,585,000 after acquiring an additional 67,820 shares in the last quarter. Finally, Susquehanna International Group LLP bought a new stake in shares of Xeris Pharmaceuticals during the 2nd quarter worth $118,000. 66.37% of the stock is owned by hedge funds and other institutional investors.

Xeris Pharmaceuticals Company Profile

Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.

Featured Story: Key terms to understand channel trading

Get a free copy of the Zacks research report on Xeris Pharmaceuticals (XERS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xeris Pharmaceuticals (NASDAQ:XERS)

Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.